Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 10:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 34 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Drug: Placebo 0mg Clear all
Completed Phase 2 Interventional Results available

Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment

NCT01170962
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
BMS-790052, Placebo, peginterferon alfa-2a, ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
35
States / cities
Montgomery, Alabama • La Jolla, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2015 · Synced Sep 27, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

Clinical Trial of Topiramate for Cocaine Addiction

NCT00685178
View directory record Official record
Conditions
Cocaine Dependence
Interventions
topiramate, Contingency Reinforcement, placebo + NonCR
Drug · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Sep 27, 2026, 10:53 AM EDT
Active, not recruiting Phase 2 Interventional

Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF

NCT05389215
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DWN12088, Placebo
Drug
Lead sponsor
Daewoong Pharmaceutical Co. LTD.
Industry
Eligibility
40 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
20
States / cities
Mesa, Arizona • Phoenix, Arizona • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 27, 2026, 10:53 AM EDT
Terminated Phase 2 Interventional Results available

Baclofen Effects on Smoking Urge and Withdrawal

NCT00257894
View directory record Official record
Conditions
Nicotine Use Disorder, Nicotine Dependence, Smoking, Tobacco Use Disorder
Interventions
Baclofen, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Sep 27, 2026, 10:53 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults

NCT01052662
View directory record Official record
Conditions
Opioid Dependence
Interventions
Memantine, Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 25 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Sep 27, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

Suvorexant to Reduce Symptoms of Nicotine Use

NCT04234997
View directory record Official record
Conditions
Smoking Cessation
Interventions
Suvorexant 20 mg, Suvorexant 0mg
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 27, 2026, 10:53 AM EDT
Terminated Phase 2 Interventional Results available

The Effects of Suvorexant on Sleep, Stress, and Cue-reactivity in Methamphetamine Use Disorder

NCT05711862
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
suvorexant (SUVO), Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 27, 2026, 10:53 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Seasonal Allergies

NCT01368445
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
azelastine hydrochloride 0.15% Nasal Spray, azelastine hydrochloride 0.15% and Placebo, Azelastine 0.1%, Nasal Spray
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
30
States / cities
Fountain Valley, California • Long Beach, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2011 · Synced Sep 27, 2026, 10:53 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Effect of Cannabis on Cigarette Use Behavior

NCT06609083
View directory record Official record
Conditions
Cannabis Use, Tobacco Use, Cigarette Smoking
Interventions
THC 30mg, THC 5mg, THC 0mg, Cigarette Full Nicotine, Cigarette Reduced Nicotine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Sep 27, 2026, 10:53 AM EDT
Recruiting Phase 3 Interventional

Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina

NCT03789552
View directory record Official record
Conditions
Chronic Stable Angina Pectoris
Interventions
T89 capsule, Placebo capsule
Drug
Lead sponsor
Tasly Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
765 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Naples, Florida
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Sep 27, 2026, 10:53 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Effect of Cannabis on E-Cigarette Use Behavior

NCT06609109
View directory record Official record
Conditions
Cannabis Use, Tobacco Use, Electronic Cigarette Use
Interventions
THC High Dose, THC Low Dose, THC 0mg, E-Cigarette Full Nicotine, E-Cigarette Placebo Nicotine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 27, 2026, 10:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Aprepitant Effects on Oxycodone Response

NCT00999544
View directory record Official record
Conditions
Narcotic Abuse
Interventions
Aprepitant 0mg, Aprepitant 40mg, Aprepitant 200mg, Oxycodone 0mg, p.o., Oxycodone 20mg, p.o., Oxycodone 40mg, p.o., Oxycodone 0mg, IN, Oxycodone 15mg, IN, Oxycodone 30mg, IN
Drug
Lead sponsor
Sharon Walsh
Other
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Sep 27, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

Psychopharmacology for Cocaine Dependence - Buspirone

NCT01267292
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Buspirone, Placebo for Buspirone, Methylphenidate, Placebo for Methylphenidate
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Sep 27, 2026, 10:53 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluate a Medication on How Hunger and Appetite Are Influenced by Smell

NCT01021176
View directory record Official record
Conditions
Food Intake
Interventions
Placebo spray, Diltiazem
Other · Drug
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 17, 2015 · Synced Sep 27, 2026, 10:53 AM EDT
Completed Phase 4 Interventional Results available

Does Duloxetine Reduce Sub-Acute Pain After Knee Arthroplasty?

NCT02005601
View directory record Official record
Conditions
Total Knee Arthroplasty
Interventions
Placebo, Duloxetine 60mg
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
25 Years to 75 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced Sep 27, 2026, 10:53 AM EDT
Withdrawn Phase 2 Interventional

Development of a Selective ALDH2 Inhibitor to Treat AUD

NCT04311294
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
ANS-6637 Low Dose, ANS-6637 High Dose, Matched Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Sep 27, 2026, 10:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pharmacokinetics of Nicotine Film in Smokers

NCT02239770
View directory record Official record
Conditions
Smoking Cessation
Interventions
Nicotine Film, Placebo Nicotine Film
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 30, 2018 · Synced Sep 27, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety, Tolerability and Efficacy of OP0201 as an Adjunct Treatment for Acute Otitis Media in Infants and Children Aged 6 to 24 Months

NCT03818815
View directory record Official record
Conditions
Acute Otitis Media
Interventions
OP0201, Placebo, Amoxicillin-clavulanate
Combination Product · Drug
Lead sponsor
Novus Therapeutics, Inc
Industry
Eligibility
6 Months to 24 Months
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Sep 27, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

Research Investigation of Soy and Estrogen

NCT00997893
View directory record Official record
Conditions
Menopause, Hot Flashes
Interventions
Soy Phytoestrogen, Estradiol, Medroxyprogesterone Acetate (MPA), Soy Placebo, MPA Placebo
Dietary Supplement · Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 6, 2020 · Synced Sep 27, 2026, 10:53 AM EDT
Completed Phase 1 Interventional Results available

Evaluation of Safety and Reduction of Ear Pain in Adults With Acute Otitis Media and Reduction of Ear Pain in Adults With Acute Otitis Media

NCT03766373
View directory record Official record
Conditions
Acute Otitis Media
Interventions
Drug: OP0201 20mg, Drug: Placebo 0mg
Combination Product
Lead sponsor
Novus Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
2
States / cities
Bellflower, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 4, 2019 · Synced Sep 27, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy of T89 in Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)

NCT03552263
View directory record Official record
Conditions
Acute Mountain Sickness (AMS)
Interventions
T89 capsule, Placebo capsule
Drug
Lead sponsor
Tasly Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Sep 27, 2026, 10:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study to Evaluate BMS-830216 in Healthy Subjects

NCT00878020
View directory record Official record
Conditions
Obesity
Interventions
BMS-830216, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2011 · Synced Sep 27, 2026, 10:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Effects of Pregabalin on Pain After Total Knee Arthroplasty

NCT01333956
View directory record Official record
Conditions
Primary Total Knee Arthroplasty
Interventions
Pregabalin 50mg, Pregabalin 100mg, Pregabalin 150mg, Placebo
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Sep 27, 2026, 10:53 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.

NCT00048581
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
42
States / cities
Birmingham, Alabama • Mobile, Alabama • Paradise Valley, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2011 · Synced Sep 27, 2026, 10:53 AM EDT